Early drug study tracks MS Candidate's journey through the body
NCT ID NCT04171310
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-stage study gave a single oral dose of a radioactive form of the experimental drug SAR442168 to 6 healthy men. Researchers measured how much of the drug was excreted in urine and stool, and how it moved through the bloodstream. The goal was to understand the drug's metabolism and elimination, which is essential before testing it in people with multiple sclerosis.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SAR442168 (oral solution)
What this could lead to
If successful, this study will help researchers understand how SAR442168 is absorbed and eliminated, which is a step toward developing a treatment for multiple sclerosis.
What could go wrong
This is a very early, small study in just 6 healthy men, not patients. It only looks at how the drug moves through the body, not whether it works for MS. Results may not predict effectiveness or safety in patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Investigational Site Number 8260001
Nottingham, United Kingdom